<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749190</url>
  </required_header>
  <id_info>
    <org_study_id>1245.10</org_study_id>
    <secondary_id>EudraCT 2008-000641-54</secondary_id>
    <nct_id>NCT00749190</nct_id>
  </id_info>
  <brief_title>BI 10773 add-on to Metformin in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control Despite Metformin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the efficacy, safety and
      pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on
      therapy to on going metformin therapy in patients with T2DM with insufficient glycemic
      control. In addition, there will be an open-label treatment arm with sitagliptin (JanuviaTM)
      as add-on therapy to metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c After 12 Weeks of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in HbA1c after 12 weeks of treatment.
In the measured values adjusted means are displayed. For means for the placebo and empagliflozin arms are from the model excluding the sitagliptin open label (OL) arm. The mean for the sitagliptin OL arm is from the model with just this treatment group and the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of FPG From Baseline After 12 Weeks of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change of Fasting Plasma Glucose (FPG) from baseline after 12 weeks of treatment. Results presented stem from a repeated measures analysis.
In the measured values adjusted means are displayed. For means for the placebo and empagliflozin arms are from the model excluding the sitagliptin open label (OL) arm. The mean for the sitagliptin OL arm is from the model with just this treatment group and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c From Baseline Over Time</measure>
    <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
    <description>Change of HbA1c from baseline over time. Results presented stem from a repeated measures analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Achieve an HbA1c â‰¤7.0% After 12 Weeks of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c less than equal to 7%) based on logistic regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c lowered at least 0.5%) based on logistic regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Results for change of FPI from baseline at week 12 based on ANCOVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>HOMA-IR (to assess insulin resistance) is defined as (FPI x FPG)/22.5. Results based on ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>HOMA-%B (to assess insulin beta cell function) is defined as (20 x FPI)/(FPG-3.5), FPG in mg/dl. Results are based on ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Body Weight After 12 Weeks of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Results for change of body weight after 12 weeks of treatment based on ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentrations of Empagliflozin in Plasma</measure>
    <time_frame>Days 28, 56 and 84</time_frame>
    <description>(Pre-dose) trough concentrations of Empagliflozin in plasma, within 30 minutes of dosing.</description>
  </secondary_outcome>
  <enrollment type="Actual">495</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously
             treated with metformin alone or with metformin and one other oral antidiabetic drug

          2. Stable metformin therapy of at least 1500 mg/day, or less if that is a maximum
             tolerated dose.

          3. HbA1c at screening 6.5% to 9.0% for patients on metformin and one other antidiabetic
             drug, and HbA1c &gt;7.0% to 10% for patients on metformin only

          4. HbA1c &gt;7.0% to 10.0% at Visit 2 (Start of Run-in)

          5. Age &gt;=18 and &lt;80years

          6. Body Mass Index (BMI) &lt;=40 kg/m2

          7. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and local legislation

        Exclusion Criteria:

          1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior
             to informed consent

          2. Impaired hepatic function

          3. Renal insufficiency or impaired renal function

          4. Diseases of the central nervous system or psychiatric disorders or clinically relevant
             neurological disorders that may interfere with participation in the trial

          5. Chronic or clinically relevant acute infections

          6. Current or chronic urogenital tract infection

          7. History of clinically relevant allergy/hypersensitivity

          8. Treatment with glitazones (e.g., rosiglitazone, pioglitazone), glucagon-like peptide
             (GLP-1) analogues, or insulin within 3 months prior to informed consent

          9. Treatment with anti-obesity drugs within 3 months prior to informed consent

         10. Treatment with systemic steroids or change in dosage of thyroid hormones within 6
             weeks prior to informed consent

         11. Alcohol abuse or drug abuse

         12. Treatment with an investigational drug within 2 months prior to informed consent

         13. Women of child-bearing potential who are nursing or pregnant, or who are not
             practicing an acceptable method of birth control, or do not plan to continue using
             this method throughout the study and do not agree to periodic pregnancy testing during
             participation in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.10.10026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwarter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Cloud</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clemson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.10025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.54008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breclav</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hodonin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.58006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kerava</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.58003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.58004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.58001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bondy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bondy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3310B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3310C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Rochelle Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Grau du Roi</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Grau du Roi</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanterre Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Narbonne Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3306B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Narbonne Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quimper</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reims Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3304B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reims Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3304C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reims Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3311A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint MandÃ©</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3311B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint MandÃ©</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3311C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint MandÃ©</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3311D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint MandÃ©</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3305C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.3305D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rehlingen-Siersburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuldiga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Talsi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.37104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ã…lesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alba Iulia</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baia Mare Maramures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.40007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.40006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Satu Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.62003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.62001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.62002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.62004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.34010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>MÃ¡laga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palma (Mallorca)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.10.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Norway</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 1 mg</title>
          <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 5 mg</title>
          <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="P4">
          <title>Empagliflozin 10 mg</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="P5">
          <title>Empagliflozin 25 mg</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="P6">
          <title>Empagliflozin 50 mg</title>
          <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="P7">
          <title>Sitagliptin OL</title>
          <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="70"/>
                <participants group_id="P7" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="65"/>
                <participants group_id="P7" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS) consisting of all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
        </group>
        <group group_id="B2">
          <title>Empa 1 mg</title>
          <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="B3">
          <title>Empa 5 mg</title>
          <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="B4">
          <title>Empa 10 mg</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="B5">
          <title>Empa 25 mg</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="B6">
          <title>Empa 50 mg</title>
          <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="B7">
          <title>Sitag</title>
          <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="71"/>
            <count group_id="B5" value="70"/>
            <count group_id="B6" value="70"/>
            <count group_id="B7" value="71"/>
            <count group_id="B8" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="8.5"/>
                    <measurement group_id="B2" value="57.4" spread="8.8"/>
                    <measurement group_id="B3" value="59.7" spread="7.3"/>
                    <measurement group_id="B4" value="59.0" spread="9.0"/>
                    <measurement group_id="B5" value="58.7" spread="8.1"/>
                    <measurement group_id="B6" value="55.9" spread="9.4"/>
                    <measurement group_id="B7" value="57.6" spread="10.1"/>
                    <measurement group_id="B8" value="58.3" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="33"/>
                    <measurement group_id="B8" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c After 12 Weeks of Treatment</title>
        <description>Change from baseline in HbA1c after 12 weeks of treatment.
In the measured values adjusted means are displayed. For means for the placebo and empagliflozin arms are from the model excluding the sitagliptin open label (OL) arm. The mean for the sitagliptin OL arm is from the model with just this treatment group and the placebo group.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set (FAS) consisting of all randomized patients who were treated with at least one dose of study drug and has a baseline measurement of the primary endpoint. The imputation method used was a modified last observation carried forward (LOCF) approach which used linear interpolation, LOCF and worst observation carried forward (WOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c After 12 Weeks of Treatment</title>
          <description>Change from baseline in HbA1c after 12 weeks of treatment.
In the measured values adjusted means are displayed. For means for the placebo and empagliflozin arms are from the model excluding the sitagliptin open label (OL) arm. The mean for the sitagliptin OL arm is from the model with just this treatment group and the placebo group.</description>
          <population>Full analysis set (FAS) consisting of all randomized patients who were treated with at least one dose of study drug and has a baseline measurement of the primary endpoint. The imputation method used was a modified last observation carried forward (LOCF) approach which used linear interpolation, LOCF and worst observation carried forward (WOCF).</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
                <count group_id="O7" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.08"/>
                    <measurement group_id="O2" value="-0.09" spread="0.08"/>
                    <measurement group_id="O3" value="-0.23" spread="0.08"/>
                    <measurement group_id="O4" value="-0.56" spread="0.08"/>
                    <measurement group_id="O5" value="-0.55" spread="0.08"/>
                    <measurement group_id="O6" value="-0.49" spread="0.08"/>
                    <measurement group_id="O7" value="-0.45" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0226</p_value>
            <p_value_desc>P-values are regarded as descriptive, adjustment for multiple testing was not necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, number of previously used anti-diabetic medications, country and baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>Difference calculated as empagliflozin 1 mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P-values are regarded as descriptive, adjustment for multiple testing was not necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, number of previously used anti-diabetic medications, country and baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
            <estimate_desc>Difference calculated as empagliflozin 5 mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values are regarded as descriptive, adjustment for multiple testing was not necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, number of previously used anti-diabetic medications, country and baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
            <estimate_desc>Difference calculated as empagliflozin 10 mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values are regarded as descriptive, adjustment for multiple testing was not necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, number of previously used anti-diabetic medications, country and baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
            <estimate_desc>Difference calculated as empagliflozin 25 mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values are regarded as descriptive, adjustment for multiple testing was not necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for treatment, number of previously used anti-diabetic medications, country and baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
            <estimate_desc>Difference calculated as empagliflozin 50 mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of FPG From Baseline After 12 Weeks of Treatment</title>
        <description>Change of Fasting Plasma Glucose (FPG) from baseline after 12 weeks of treatment. Results presented stem from a repeated measures analysis.
In the measured values adjusted means are displayed. For means for the placebo and empagliflozin arms are from the model excluding the sitagliptin open label (OL) arm. The mean for the sitagliptin OL arm is from the model with just this treatment group and the placebo group.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS using modified LOCF imputation method</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of FPG From Baseline After 12 Weeks of Treatment</title>
          <description>Change of Fasting Plasma Glucose (FPG) from baseline after 12 weeks of treatment. Results presented stem from a repeated measures analysis.
In the measured values adjusted means are displayed. For means for the placebo and empagliflozin arms are from the model excluding the sitagliptin open label (OL) arm. The mean for the sitagliptin OL arm is from the model with just this treatment group and the placebo group.</description>
          <population>FAS using modified LOCF imputation method</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="69"/>
                <count group_id="O7" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="3.48"/>
                    <measurement group_id="O2" value="-1.70" spread="3.49"/>
                    <measurement group_id="O3" value="-15.84" spread="3.45"/>
                    <measurement group_id="O4" value="-22.14" spread="3.49"/>
                    <measurement group_id="O5" value="-26.83" spread="3.47"/>
                    <measurement group_id="O6" value="-27.91" spread="3.47"/>
                    <measurement group_id="O7" value="-12.92" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of HbA1c From Baseline Over Time</title>
        <description>Change of HbA1c from baseline over time. Results presented stem from a repeated measures analysis.</description>
        <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
        <population>FAS. Imputation method used was the classical LOCF (CLOCF) approach which uses always the last available value.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of HbA1c From Baseline Over Time</title>
          <description>Change of HbA1c from baseline over time. Results presented stem from a repeated measures analysis.</description>
          <population>FAS. Imputation method used was the classical LOCF (CLOCF) approach which uses always the last available value.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
                <count group_id="O7" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.06"/>
                    <measurement group_id="O2" value="-0.12" spread="0.06"/>
                    <measurement group_id="O3" value="-0.16" spread="0.06"/>
                    <measurement group_id="O4" value="-0.32" spread="0.06"/>
                    <measurement group_id="O5" value="-0.31" spread="0.06"/>
                    <measurement group_id="O6" value="-0.36" spread="0.06"/>
                    <measurement group_id="O7" value="-0.26" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.07"/>
                    <measurement group_id="O2" value="-0.14" spread="0.07"/>
                    <measurement group_id="O3" value="-0.30" spread="0.07"/>
                    <measurement group_id="O4" value="-0.57" spread="0.07"/>
                    <measurement group_id="O5" value="-0.52" spread="0.07"/>
                    <measurement group_id="O6" value="-0.53" spread="0.07"/>
                    <measurement group_id="O7" value="-0.40" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.08"/>
                    <measurement group_id="O2" value="-0.08" spread="0.08"/>
                    <measurement group_id="O3" value="-0.27" spread="0.08"/>
                    <measurement group_id="O4" value="-0.57" spread="0.08"/>
                    <measurement group_id="O5" value="-0.59" spread="0.08"/>
                    <measurement group_id="O6" value="-0.50" spread="0.08"/>
                    <measurement group_id="O7" value="-0.45" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Achieve an HbA1c â‰¤7.0% After 12 Weeks of Treatment</title>
        <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c less than equal to 7%) based on logistic regression</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Achieve an HbA1c â‰¤7.0% After 12 Weeks of Treatment</title>
          <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c less than equal to 7%) based on logistic regression</description>
          <population>FAS (CLOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
                <count group_id="O7" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="23.9"/>
                    <measurement group_id="O3" value="21.1"/>
                    <measurement group_id="O4" value="38.0"/>
                    <measurement group_id="O5" value="37.1"/>
                    <measurement group_id="O6" value="35.7"/>
                    <measurement group_id="O7" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment</title>
        <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c lowered at least 0.5%) based on logistic regression</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment</title>
          <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c lowered at least 0.5%) based on logistic regression</description>
          <population>FAS (CLOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
                <count group_id="O7" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="31.0"/>
                    <measurement group_id="O3" value="40.8"/>
                    <measurement group_id="O4" value="60.6"/>
                    <measurement group_id="O5" value="60.0"/>
                    <measurement group_id="O6" value="48.6"/>
                    <measurement group_id="O7" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)</title>
        <description>Results for change of FPI from baseline at week 12 based on ANCOVA</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)</title>
          <description>Results for change of FPI from baseline at week 12 based on ANCOVA</description>
          <population>FAS (CLOCF)</population>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.57"/>
                    <measurement group_id="O2" value="0.09" spread="0.59"/>
                    <measurement group_id="O3" value="-0.84" spread="0.58"/>
                    <measurement group_id="O4" value="-1.77" spread="0.58"/>
                    <measurement group_id="O5" value="-0.11" spread="0.59"/>
                    <measurement group_id="O6" value="-1.52" spread="0.57"/>
                    <measurement group_id="O7" value="1.84" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)</title>
        <description>HOMA-IR (to assess insulin resistance) is defined as (FPI x FPG)/22.5. Results based on ANCOVA.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR (to assess insulin resistance) is defined as (FPI x FPG)/22.5. Results based on ANCOVA.</description>
          <population>FAS (CLOCF)</population>
          <units>mU/L x mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.26"/>
                    <measurement group_id="O2" value="-0.11" spread="0.27"/>
                    <measurement group_id="O3" value="-0.60" spread="0.26"/>
                    <measurement group_id="O4" value="-1.04" spread="0.26"/>
                    <measurement group_id="O5" value="-0.52" spread="0.27"/>
                    <measurement group_id="O6" value="-1.10" spread="0.27"/>
                    <measurement group_id="O7" value="0.48" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)</title>
        <description>HOMA-%B (to assess insulin beta cell function) is defined as (20 x FPI)/(FPG-3.5), FPG in mg/dl. Results are based on ANCOVA.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)</title>
          <description>HOMA-%B (to assess insulin beta cell function) is defined as (20 x FPI)/(FPG-3.5), FPG in mg/dl. Results are based on ANCOVA.</description>
          <population>FAS (CLOCF)</population>
          <units>mU / mmol</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="2.70"/>
                    <measurement group_id="O2" value="0.08" spread="2.77"/>
                    <measurement group_id="O3" value="0.36" spread="2.76"/>
                    <measurement group_id="O4" value="1.55" spread="2.72"/>
                    <measurement group_id="O5" value="6.68" spread="2.78"/>
                    <measurement group_id="O6" value="4.01" spread="2.76"/>
                    <measurement group_id="O7" value="12.38" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Body Weight After 12 Weeks of Treatment</title>
        <description>Results for change of body weight after 12 weeks of treatment based on ANCOVA.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O6">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O7">
            <title>Sitagliptin OL</title>
            <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Body Weight After 12 Weeks of Treatment</title>
          <description>Results for change of body weight after 12 weeks of treatment based on ANCOVA.</description>
          <population>FAS (CLOCF)</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
                <count group_id="O7" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="0.31"/>
                    <measurement group_id="O2" value="-1.55" spread="0.31"/>
                    <measurement group_id="O3" value="-2.28" spread="0.31"/>
                    <measurement group_id="O4" value="-2.74" spread="0.31"/>
                    <measurement group_id="O5" value="-2.56" spread="0.31"/>
                    <measurement group_id="O6" value="-2.85" spread="0.32"/>
                    <measurement group_id="O7" value="-0.84" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Concentrations of Empagliflozin in Plasma</title>
        <description>(Pre-dose) trough concentrations of Empagliflozin in plasma, within 30 minutes of dosing.</description>
        <time_frame>Days 28, 56 and 84</time_frame>
        <population>All patients who received at least one dose of Empagliflozin and have some Pharmacokinetic (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 1 mg</title>
            <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Empagliflozin 50 mg</title>
            <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentrations of Empagliflozin in Plasma</title>
          <description>(Pre-dose) trough concentrations of Empagliflozin in plasma, within 30 minutes of dosing.</description>
          <population>All patients who received at least one dose of Empagliflozin and have some Pharmacokinetic (PK) data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (N=58, 65, 62, 58, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="88.8"/>
                    <measurement group_id="O2" value="13.1" spread="79.4"/>
                    <measurement group_id="O3" value="27.3" spread="127"/>
                    <measurement group_id="O4" value="92.5" spread="111"/>
                    <measurement group_id="O5" value="119" spread="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (N=56, 64, 64, 61, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="69.6"/>
                    <measurement group_id="O2" value="11.5" spread="63.2"/>
                    <measurement group_id="O3" value="23.0" spread="93.8"/>
                    <measurement group_id="O4" value="75.4" spread="140"/>
                    <measurement group_id="O5" value="119" spread="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (N=53, 61, 59, 57, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="80.1"/>
                    <measurement group_id="O2" value="11.2" spread="69.6"/>
                    <measurement group_id="O3" value="23.4" spread="85.1"/>
                    <measurement group_id="O4" value="71.0" spread="111"/>
                    <measurement group_id="O5" value="112" spread="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study medication until 7 days following the last intake of study medication, up to 100 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 1 mg</title>
          <description>Patients receive 1 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 5 mg</title>
          <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="E4">
          <title>Empagliflozin 10 mg</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="E5">
          <title>Empagliflozin 25 mg</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="E6">
          <title>Empagliflozin 50 mg</title>
          <description>Patients receive 50 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="E7">
          <title>Sitagliptin OL</title>
          <description>Patients receive 100 mg Sitagliptin (open-label) in tablets once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

